THNR - ETF AI Analysis

Top Page

Amplify Weight Loss Drug & Treatment ETF (THNR)

Rating:67Neutral

Price Target:―

THNR, the Amplify Weight Loss Drug & Treatment ETF, earns a solid overall rating largely because its biggest positions, Eli Lilly and Novo Nordisk, are financially strong leaders in weight-loss and diabetes treatments, supported by positive earnings outlooks and long-term growth strategies. Additional high-quality holdings like Merck, Regeneron, and Amgen further support the fund with strong balance sheets, innovation pipelines, and generally favorable technical trends, though some names such as AbbVie and Pfizer face valuation, debt, and revenue-growth challenges that slightly temper the fund’s appeal. The main risk is the fund’s concentration in a single, highly specialized healthcare niche, where regulatory changes, competition, or setbacks in key drugs could significantly impact performance.

Positive Factors

Strong Holdings Performance

Several top holdings, like Amgen and Roche, have shown strong year-to-date gains, supporting the ETF's overall performance.

Focused Sector Exposure

The ETF is heavily concentrated in the health care sector, which benefits from steady demand and innovation in treatments.

Global Diversification

The fund includes exposure to international markets like Hong Kong, Japan, and Switzerland, reducing reliance on U.S. performance alone.

Negative Factors

Underperforming Key Holdings

Some major positions, such as Novo Nordisk and Regeneron, have lagged in performance, which could drag on returns.

High Expense Ratio

The ETF charges a relatively high expense ratio compared to broader market funds, which can eat into investor returns over time.

Sector Over-Concentration

With over 93% of assets in health care, the fund is highly sensitive to risks specific to that sector.

THNR vs. SPDR S&P 500 ETF (SPY)

AUM3.90M

RegionDeveloped Markets

Expense Ratio0.59%

Beta0.71

IssuerAmplify

Inception DateMay 21, 2024

Dividend Yield1.6%

Asset ClassEquity

Index TrackedVettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume1,124

30 Day Avg. Volume2,081

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

29.37

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

THNR Summary

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an investment fund focused on companies in the health care sector, particularly those developing weight loss drugs and treatments. It includes well-known companies like Eli Lilly and Novo Nordisk, which are leaders in pharmaceuticals and biotechnology. This ETF could be appealing to investors looking to benefit from the growing demand for innovative health solutions and diversify their portfolio with exposure to the health care industry. However, new investors should be aware that the ETF’s performance is closely tied to the health care sector, which can be affected by regulatory changes or shifts in market demand.

How much will it cost me?The Amplify Weight Loss Drug & Treatment ETF (THNR) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise required to select investments.

What would affect this ETF?The Amplify Weight Loss Drug & Treatment ETF (THNR) could benefit from growing global awareness of obesity-related health issues and increased demand for innovative weight loss treatments, especially as its top holdings include major pharmaceutical companies like Eli Lilly and Novo Nordisk, which are leaders in this space. However, the ETF may face challenges from regulatory hurdles, competition in drug development, or economic downturns that could reduce consumer spending on health care solutions. Additionally, its heavy reliance on the health care sector makes it vulnerable to sector-specific risks, such as changes in government policies or patent expirations.

THNR Top 10 Holdings

The Amplify Weight Loss Drug & Treatment ETF (THNR) is heavily concentrated in the health care sector, with a focus on pharmaceutical and biotech giants driving innovation in weight loss treatments. Eli Lilly is a standout performer, steadily rising on the back of strong financial results and promising drug developments, while Novo Nordisk has been lagging recently due to market share challenges. Regeneron and Roche are adding momentum with robust pipelines and bullish technical signals, while AbbVie and Pfizer are holding the fund back with mixed performance and profitability concerns. Overall, the ETF’s developed markets exposure reflects a strategic bet on transformative health care advancements.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
NVO	Novo Nordisk	14.19%	$553.28K	$261.54B	-29.08%	73 Outperform
LLY	Eli Lilly & Co	12.68%	$494.43K	$1.01T	43.73%	72 Outperform
AMGN	Amgen	6.51%	$253.93K	$177.14B	22.32%	77 Outperform
REGN	Regeneron	6.46%	$251.96K	$79.26B	7.21%	78 Outperform
4519	Chugai Pharmaceutical Co	6.26%	$244.19K	¥14.02T	28.71%	74 Outperform
MRK	Merck & Company	5.23%	$203.75K	$275.53B	10.24%	80 Outperform
ROG	Roche Holding AG	5.08%	$198.19K	CHF275.00B	44.94%	73 Outperform
AZN	AstraZeneca	5.00%	$195.07K	$298.79B	46.68%	79 Outperform
4507	Shionogi & Co	5.00%	$194.93K	¥2.59T	24.96%	75 Outperform
1801	Innovent Biologics	4.99%	$194.73K	HK$155.16B	186.75%	61 Neutral

THNR Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

24.97

Positive

100DMA

24.03

Positive

200DMA

22.90

Positive

Market Momentum

MACD

0.34

Positive

RSI

56.57

Neutral

STOCH

62.58

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For THNR, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 25.60, equal to the 50-day MA of 24.97, and equal to the 200-day MA of 22.90, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 56.57 is Neutral, neither overbought nor oversold. The STOCH value of 62.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for THNR.

THNR Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
THNR	―	―	$3.90M	0.59%	―
AGNG	―	―	$77.92M	0.50%	―
JEDI	―	―	$42.40M	0.69%	―
WISE	―	―	$39.50M	0.35%	―
PBOG	―	―	$11.66M	0.13%	―
PBPH	―	―	$11.26M	0.13%	―

Performance Comparison

THNR

Amplify Weight Loss Drug & Treatment ETF

25.83

4.11

18.92%

AGNG

Global X Aging Population ETF

―

JEDI

Defiance Drone and Modern Warfare ETF

―

WISE

Themes Generative Artificial Intelligence ETF

―

PBOG

Portfolio Building Block Integrated Oil and Gas and Exploration and Production Index ETF

―

PBPH

Portfolio Building Block World Pharma and Biotech Index ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents